Advanced Resin Therapeutics Overview
Latest Deal Type
Later Stage VC
(Upcoming)
Advanced Resin Therapeutics General Information
Description
Operator of a specialty pharmaceutical company intended to conduct research and development of a resin, trans-mucosal systemic delivery of active ingredients focused on the central nervous system. The company's formulations are designed to provide quick delivery of alprazolam for anxiety, ondansetron for nausea, sumitriptan for migraines, fentanyl for pain, Vardenafil and Sildenafil for erectile dysfunction and nicotine as an aid to smoking cessation, providing medical practitioners with a drug delivery system that promotes topical and transmucosal delivery of medications more efficiently and effectively than current technologies.
Want to dig into this profile?
We’ll help you find what you need
Learn more
Advanced Resin Therapeutics Valuation & Funding
| Deal Type |
Date |
Amount |
Raised to Date |
Post-Val |
Status |
Stage |
| 4. Later Stage VC |
|
$2.5M |
|
|
Upcoming |
|
| 3. Later Stage VC |
03-Apr-2017 |
00.00 |
00.000 |
00.00 |
Completed |
Generating Revenue |
| 2. Accelerator/Incubator |
12-May-2016 |
|
$454K |
|
Completed |
Generating Revenue |
| 1. Later Stage VC |
27-May-2011 |
$454K |
$454K |
|
Completed |
Generating Revenue |
Advanced Resin Therapeutics Executive Team (5)
| Name |
Title |
Board Seat |
Contact Info |
| Howard Edelman |
Chief Executive Officer |
|
|
| Tracey Forester |
Chief Marketing Officer |
|
|
| Alex Battaglia Ph.D |
Co-Founder, Chief Scientific Officer & Board Member |
|
|
| Eva Beim |
Co-Founder, Executive Vice President of Strategic Relations and Global Business Development |
|
|
1 Former Executive